After years of effort and experience, Creative Biolabs has successfully developed a world-leading NHP disease model platform. We are now providing a one-stop preclinical service for global researchers using our well-characterized NHP models to facilitate their cutting-edge programs best. Particularly, our scientists are proud to introduce our metabolic disorder models to worldwide customers.
The increased prevalence of metabolic disorders (e.g. type I diabetes, type II diabetes, and diet-induced obesity) brings an enormous risk to human society. With the continuously aging and increasing population, the unabated rise in these diseases is not likely to slow down in the near future. Therefore, effective treatments are urgently required, constituting a big challenge for human healthcare.
Animal models play important roles in determining the pathogenesis of and effective treatments for obesity and diabetes. Non-human primates (NHPs) are particularly useful for studying these disorders in comparison to other animal species, they share so many similarities with human beings in physiology, anatomy, behavior, organ mechanisms, immunology, etc.
Type I diabetes is characterized by little or no insulin and occurs in an extremely low incidence in NHPs. We provide the well-established NHP type I diabetes induced by systemic administration of streptozotocin (STZ).
Type II diabetes represents a long-term metabolic disease status, which is mainly characterized by insulin resistance, high blood sugar and relative lack of insulin. Our company provides high-fat diet (HFD)-induced diabetic monkeys with lots of similarities to human diabetics.
We can conduct a comprehensive range of validated measures to evaluate the modeling outcomes and drug efficacy, including but not limited to:
Obesity is a body condition in which excess body fat has accumulated to some extent that may cause many health risks.
We provide the well-characterized diet-induced obesity (DIO) model induced via feeding with a high calorie (fat) diet (HCD). Spontaneous Obesity Model is also available upon request. Multidimensional endpoint measurements are provided according to customers' requirements:
Dyslipidemia, an abnormality of lipoprotein metabolism, is also a metabolic disorder disease. It mainly includes elevated total cholesterol and low-density lipoprotein cholesterol, elevated triglycerides, and/or decreased high-density lipoprotein cholesterol. We not only provide the well-established dyslipidemia model in NHPs, but also the related analysis services including blood biochemistry, fecal total bile acid levels measurement, lipid levels in the feces measurement, apoB, apoAI, LDL, and HDL levels determination (by SDS-PAGE, LC/MS), plasma concentrations of EPA and DPA, Omega-3 index analysis, etc. to advance your preclinical study projects.
Creative Biolabs has years of experience in the field of building NHP disease models. In addition, we have also integrated the following NHP models (e.g. neurological disease, renal disease, liver disease, urogenital disease, and immune disease) to fulfill customs' needs. We are pleased to leverage our abundant NHP resources as well as the unparalleled expertise to provide the best assistance for our clients. Please feel free to contact us for further discussions.
For Research Use Only.
